Cardiomyocytes Market - Regional Analysis
North America Market Insights
The cardiomyocytes market in the North American region, amongst the market in all the other regions, is anticipated to hold the largest with a share of about ~35% by the end of 2035. The market growth in the region is expected to grow on account of the presence of major key players such as Axol Bioscience Ltd, Cell Applications Inc., Cellular Dynamics International, and R&D Systems Inc. in the region. Moreover, the Boston-Cambridge biotech cluster and San Francisco Bay Area Silicon Valley in the United States serve as the epicenter of cardiomyocyte research investments and entrepreneurship. Additionally, the high prevalence of cardiovascular disease due to unhealthy lifestyles in the region is also expected to further propel the market growth. According to data published by a government website about 695,000 people in the United States died from heart disease in 2021. Increasing the demand for newer and more effective forms of treatment like cardiomyocyte therapies in the region.
APAC Market Insights
North America industry is predicted to hold largest revenue share of 35% by 2035. The market’s expansion can be attributed majorly to the increasing demand for cardiac testing in fast-emerging countries such as India, China, Vietnam, and Indonesia, as a result of rising cardiovascular diseases in the region. According to research around 5 million people in India died due to cardiovascular diseases in 2020 and an estimated 4.58 million deaths occurred in 2020 in China due to cardiovascular disease. Furthermore, the growing aging population of this region due to increasing longevity and falling fertility is also expected to propel the market growth. For instance, in 2020 there were an estimated 140 million people aged 60 and above in India, and in 2019 an estimated 250 million people in China were aged 60 years or older. Thus, increasing the demand for cardiomyocytes in the Asia-Pacific region.
